1. Date of download: 9/16/2016 From: Should All Patients with Type 1 Diabetes Mellitus and Microalbuminuria Receive Angiotensin-Converting Enzyme Inhibitors?: A Meta-Analysis of Individual Patient Data Ann Intern Med. 2001;134(5):370-379. doi:10.7326/0003-4819-134-5-200103060-00009 Estimated difference in albumin excretion rate between placebo and treatment groups at 2 years, using 1-year data only.ATLANTIS = ACE Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects; ESPRIT = European Study of the Progression of Renal Disease in Type 1 Diabetes; EUCLID = EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes; IDDM = insulin-dependent diabetes mellitus; IMSG = Italian Microalbuminuria Study Group; MDNSG = Melbourne Diabetic Nephropathy Study Group; PRIMA = Project with Ramipril on Insulin dependent patients with MicroalbuminuriA. Error bars represent 95% CIs. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2. Date of download: 9/16/2016 From: Should All Patients with Type 1 Diabetes Mellitus and Microalbuminuria Receive Angiotensin-Converting Enzyme Inhibitors?: A Meta-Analysis of Individual Patient Data Ann Intern Med. 2001;134(5):370-379. doi:10.7326/0003-4819-134-5-200103060-00009 Estimated difference in albumin excretion rate between placebo and treatment groups at 2 years, using varying periods of follow-up.Error bars represent 95% CIs. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3. Date of download: 9/16/2016 From: Should All Patients with Type 1 Diabetes Mellitus and Microalbuminuria Receive Angiotensin-Converting Enzyme Inhibitors?: A Meta-Analysis of Individual Patient Data Ann Intern Med. 2001;134(5):370-379. doi:10.7326/0003-4819-134-5-200103060-00009 Estimated difference in albumin excretion rate between placebo and treatment groups at 2 years, according to albuminuric status at baseline.PValues are estimated from the regression model. = 0.04 for treatment effect on continuous baseline albumin excretion rate. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

4. Date of download: 9/16/2016 From: Should All Patients with Type 1 Diabetes Mellitus and Microalbuminuria Receive Angiotensin-Converting Enzyme Inhibitors?: A Meta-Analysis of Individual Patient Data Ann Intern Med. 2001;134(5):370-379. doi:10.7326/0003-4819-134-5-200103060-00009 Risk for progression to macroalbuminuria (top) and regression to normoalbuminuria (bottom).P(23)Because the estimate of between-study variance was zero for progression to macroalbuminuria, the fixed-effects model was the same as the random-effects model ( > 0.5 for heterogeneity). *Zero events in the placebo group indicates a between-study variance of 0.22, using the Van Houwelingen method with likelihood based on confidence intervals. ATLANTIS = ACE Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects; ESPRIT = European Study of the Progression of Renal Disease in Type 1 Diabetes; EUCLID = EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes; IDDM = insulin-dependent diabetes mellitus; IMSG = Italian Microalbuminuria Study Group; MDNSG = Melbourne Diabetic Nephropathy Study Group; PRIMA = Project with Ramipril on Insulin dependent patients with MicroalbuminuriA. Error bars represent 95% CIs. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians